PETACH TIKVA, Israel, April 17, 2019 /CNW/ - Medison Biotech (1995) Ltd. (" Medison "), which together with its affiliates owns more than 10.4 million shares or 7.3% of Knight Therapeutics, Inc. (TSX: GUD ) ( "Knight" or the "Company" ), today disclosed that an independent report authored by leading corporate governance expert Dr. Richard Leblanc (the " Leblanc Report ") reveals and confirms acute conflicts of interest and governance deficiencies at Knight.